New drug trial aims to reverse liver damage in MASH patients
NCT ID NCT06937749
Summary
This study is testing whether an experimental drug called IBI362 can help people with MASH, a serious form of fatty liver disease that causes inflammation and scarring. About 165 adults with confirmed MASH will receive either a low dose, high dose, or a placebo (inactive substance) for 60 weeks to see if the drug improves liver health. The main goal is to see if the drug can resolve liver inflammation without worsening existing scarring.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tsinghua Changgung Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.